Next Article in Journal
An Injectable Hyaluronan–Methylcellulose (HAMC) Hydrogel Combined with Wharton’s Jelly-Derived Mesenchymal Stromal Cells (WJ-MSCs) Promotes Degenerative Disc Repair
Next Article in Special Issue
Research of Pathogenesis and Novel Therapeutics in Arthritis 2.0
Previous Article in Journal
Is the Secret of VDAC Isoforms in Their Gene Regulation? Characterization of Human VDAC Genes Expression Profile, Promoter Activity, and Transcriptional Regulators
Previous Article in Special Issue
The Interplay between Transcriptional Factors and MicroRNAs as an Important Factor for Th17/Treg Balance in RA Patients
Review

Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis

1
Department of Internal Medicine, Rheumatology and Clinical Immunology, Faculty in Katowice, Medical University of Silesia, 40-635 Katowice, Poland
2
Department of Haematology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia
3
Department of Physiotherapy in Internal Medicine, Academy of Physical Education in Katowice, 40-065 Katowice, Poland
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(19), 7390; https://doi.org/10.3390/ijms21197390
Received: 14 September 2020 / Revised: 2 October 2020 / Accepted: 3 October 2020 / Published: 7 October 2020
(This article belongs to the Special Issue Research of Pathogenesis and Novel Therapeutics in Arthritis 2.0)
Janus kinase (JAK) inhibitors, a novel class of targeted synthetic disease-modifying antirheumatic drugs (DMARDs), have shown their safety and efficacy in rheumatoid arthritis (RA) and are being intensively tested in other autoimmune and inflammatory disorders. Targeting several cytokines with a single small compound leads to blocking the physiological response of hundreds of genes, thereby providing the background to stabilize the immune response. Unfortunately, blocking many cytokines with a single drug may also bring some negative consequences. In this review, we focused on the activity of JAK inhibitors in the cardiovascular system of patients with RA. Special emphasis was put on the modification of heart performance, progression of atherosclerosis, lipid profile disturbance, and risk of thromboembolic complications. We also discussed potential pathophysiological mechanisms that may be responsible for such JAK inhibitor-associated side effects. View Full-Text
Keywords: rheumatoid arthritis; JAK/STAT; Janus kinase inhibitors; cardiovascular system; heart failure; thromboembolic; lipid profile disturbances; cytokines rheumatoid arthritis; JAK/STAT; Janus kinase inhibitors; cardiovascular system; heart failure; thromboembolic; lipid profile disturbances; cytokines
Show Figures

Graphical abstract

MDPI and ACS Style

Kotyla, P.J.; Islam, M.A.; Engelmann, M. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis. Int. J. Mol. Sci. 2020, 21, 7390. https://doi.org/10.3390/ijms21197390

AMA Style

Kotyla PJ, Islam MA, Engelmann M. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis. International Journal of Molecular Sciences. 2020; 21(19):7390. https://doi.org/10.3390/ijms21197390

Chicago/Turabian Style

Kotyla, Przemysław J., Md A. Islam, and Małgorzata Engelmann. 2020. "Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis" International Journal of Molecular Sciences 21, no. 19: 7390. https://doi.org/10.3390/ijms21197390

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop